Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Shares Climb Again

NEW YORK (GenomeWeb News) – Shares of Sequenom rose around 20 percent for the second straight day after the firm reported yesterday that a blinded study showed that its molecular test for Down syndrome correctly identified 100 percent of all Down syndrome samples without any false-positive outcomes.
 
That announcement pushed Sequenom’s shares up 22 percent yesterday.
 
Today, in heavy trading on the Nasdaq — around 10 times its average daily volume — shares of Sequenom climbed another 19.5 percent to close at $11.15.
The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.